This page is updated frequently with new Leukocyte-related patent applications.
|Method for labeling intracellular and extracellular targets of leukocytes|
The present invention relates to methods for labeling intracellular and extracellular targets of leukocytes, as well as to kits for performing said methods.. .
Beckman Coulter, Inc.
|Influenza-specific t-cell receptor and its uses in the detection, prevention and/or treatment of influenza|
The present invention relates to specific t-cell receptor a-chains, t-cell receptor β-chains and t-cell receptors comprising said t-cell receptor a-chain and/or β-chain. In particular, the invention relates to t-cell receptors and/or chains binding to the influenza matrix peptide gilgfvftl (gl9 peptide) presented by human leukocyte antigen a2 (hla-a2) molecules.
Friedrich-alexander UniversitÄt Erlangen-nÜrnberg
|Compositions and methods to image and quantify inflammation|
Compositions and methods for assessing inflammation in a subject. The present disclosure provides compositions for labeling leukocytes with a 19f-containing perfluoropolyether molecule ex vivo.
|Diagnosis and treatment of autoimmune diseases|
The invention relates generally to the field of autoimmunity. More specifically, the invention relates to compositions and methods for the diagnosis, prevention, and treatment of human leukocyte antigen (hla)-associated autoimmune diseases, and in particular hla-b27-associated autoimmune diseases..
Newsouth Innovations Pty Limited
|Method for treating a blood component containing sample|
Provided is a treatment method for damaging an erythrocyte and a leukocyte while suppressing damage to cells other than blood cells present in blood. In an embodiment, the disclosure relates to a method for treating a sample containing blood components, the method including mixing a sample containing blood components with a surfactant a, where the surfactant a is a nonionic surfactant represented by general formula r1—o-(eo)n-r2 (i)..
|Disease therapy by inducing immune response to trop-2 expressing cells|
The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for trop-2 (egp-1) and at least one binding site for cd3. The bispecific antibodies are of use for inducing an immune response against a trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate.
Ibc Pharmaceuticals, Inc.
|Method for obtaining a cytokine-rich composition and composition obtained by means of this method|
The invention relates to a method for preparing serums, said serums comprising cytokines and coagulation factors, and for preparing fibrin gel compositions, wherein the method comprises submitting an isolated biological sample comprising platelets and/or leukocytes to different steps of different gravity force to obtain supernatants with high concentrations of cytokines and coagulation factors. The invention also encompasses serums obtainable by this method, and other derived products comprising them.
Nte-sener Healthcare, S.a.
|Mass spectrometric diagnosis of sepsis without blood culture|
The invention relates to methods and instruments for the rapid detection and rapid mass spectrometric identification of microbial infective agents in blood or other body fluids. The invention recognizes that blood is not a good environment for the cultivation of microbes and provides a method which (a) largely destroys or dissolves the human particles in body fluids, such as erythrocytes and leukocytes in blood, without impairing the ability of the microbes to reproduce, (b) separates the microbial pathogens from the fluid, (c) cultivates them in a nutrient broth which contains none of the antimicrobial components of the body fluids, (d) separates them from the nutrient broth, and (e) identifies the microbes by a mass spectrum of the microbial proteins.
|Compositions and methods to image and quantify inflammation|
Compositions and methods for assessing inflammation in a subject. The preset disclosure provides compositions for labeling leukocytes with a 19f-containing perfluoropolyether molecule ex vivo.
|Molecular imaging methods for diagnosis and evaluation of ocular and systemic diseases|
This invention relates generally to minimally-invasive, in vivo methods of detecting one or more ligands on an intraluminal surface of a blood vessel using microparticles coated with one or more ligand binding partners. More particularly, in certain embodiments, the invention relates to minimally-invasive, in vivo methods of detecting endothelial and leukocyte antigens that are predictive of diabetic retinopathy (dr) and/or other conditions using protein-conjugated microparticles detectable by a non-invasive detection system, for example, a scanning laser ophthalmoscope.
Massachusetts Eye And Ear Infirmary
Plif multimeric peptides and uses thereof
Provided is a multimeric peptide comprising at least two peptide monomers linked to one another, each of the at least two peptide monomers comprising at least 6 consecutive amino acids from the amino acid sequence as set forth in seq id no: 1, wherein the at least two peptide monomers are each no longer than 30 amino acids, wherein the multimeric peptide is capable of reducing binding of placenta immunomodulatory factor (plif) to human leukocytes.. .
Ramot At Tel-aviv University Ltd.
Agents for the molecular imaging of serine-protease in human pathologies
The present invention is directed to the use of an irreversible ligand of a serine protease selected from the group consisting of leukocyte elastase, thrombin, tissue plasminogen activator (t-pa) and plasmin for the molecular imaging of said serine protease and the diagnosis of pathophysiological conditions associated with said serine protease activity.. .
Universite Paris Diderot - Paris 7
Acellular pro-inflammatory compositions, process for making same and methods of using same
This invention relates to acellular-based therapies for decreasing the level of regulatory t cells (treg) and/or increasing the level of pro-inflammatory t cells (th17) to favor immune stimulation. To provide these therapeutic effects, an allogeneic leukocyte population is contacted with another leukocyte population and the acellular components produced are isolated.
Canadian Blood Services
Blood analysis method, control device, and blood cell analyzer
The present disclosure provided a blood cell analyzer, a control device and a blood analysis method thereof. In the method, a first reagent is mixed with a sample to obtain a first testing sample, and then a second reagent is mixed with the first testing sample for a further reaction to get a second testing sample for basophil classification and/or hgb measurement.
Shenzhen Mindray Bio-medical Electronics Co., Ltd.
Leukocyte esterase detection from throat swab
The present invention relates to the field of infectious diseases. The invention specifically relates to the diagnostic test for acute bacterial pharyngitis.
Methods for inducing the differentiation of blood monocytes into functional dendritic cells
Methods are provided for treating blood monocytes to produce functional antigen presenting dendritic cells. An extracorporeal quantity of a subject's blood is treated to separate the blood and produce a leukocyte concentrate comprising monocytes and plasma containing proteins.
Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
The hiv-specific cytotoxic t lymphocyte (ctl) response is a critical component in controlling hiv replication and is an important part of the ultimate failure to eradicate the virus. Disclosed herein are methods for genetically enhancing the hiv-specific ctl response to allow long-term viral suppression or viral clearance.
The Regents Of The University Of California
Method to functionalize cells in human blood, other fluids and tissues using nanoparticles
Compositions and methods for inhibiting metastatic cancer cells. The compositions comprise nanoparticles which have incorporated therein leukocyte adhesion molecules and therapeutic molecules exposed on their surface.
Allogeneic tumor cell vaccination
The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions.
Download all patent PDFs.
Bulk PDF Downloads25% Off COUPON CODE: mypdfs
High efficiency microfluidic purification of stem cells to improve transplants
Described herein is a novel, highly efficient system to remove erythrocytes and purify leukocytes would raise the quality of ucb and other transplant grafts, thereby significantly improving patient outcomes.. .
The Trustees Of Princeton University
Reducing the immunogenicity of allografts
(c) isolating the passenger leukocytes from the recirculating perfusion solution to prevent the passenger leukocytes from re-entering the tissue or organ.. .
Receptors for b7-h4
Isolated cell surface receptors for b7-h4 have been identified based on function. B7-h4 receptor activation by b7-h4 on the dendritic cell, t follicular helper cell and germinal center b cell membrane stimulates inhibitory signaling in those leukocytes.
Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
The present invention provides novel antibodies specifically bind to an epitope on cd43 and cea expressed on nonhematopoietic cancer cells, but do not specifically bind to a cd43 expressed by a leukocyte or by a jurkat cell, and is capable of inducing apoptosis of the nonhematopoietic cancer cell after binding to the epitope on cell surface of the nonhematopoietic cancer cell in the absence of cytotoxin conjugation and immune effector function, wherein the epitope comprises a carbohydrate structure and the binding of the antibody to the epitope is inhibited by a carbohydrate comprising a lea structure, a lea-lactose structure, a lndfh ii structure, or a lnt structure. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes..
Methods and devices for high throughput purification
Described herein are devices and methods for high throughput purification of particles. In some cases, methods and devices described herein can be used to remove erythrocytes and purify leukocytes and raise the quality of umbilical cord blood and other transplant grafts, thereby significantly improving patient outcomes..
University Of Maryland, Baltimore
Described herein are particular embodiments relating to a microfluidic device that may be utilized for cell sensing, counting, and/or sorting. Particular aspects relate to a microfabricated device that is capable of differentiating single cell types from dense cell populations.
California Institute Of Technology
Mass spectrometric diagnosis of septicemia
The invention mainly relates to the mass spectrometric identification of pathogens in blood cultures from bloodstream infections (septicemia). The invention provides a method with which microbial pathogens can be separated in purified form from blood after a relatively brief cultivation in a blood culture flask, without any interfering human proteins or any residual fractions of blood particles such as erythrocytes and leukocytes, and can be directly identified by mass spectrometric measurement of their protein profiles.
Bruker Daltonik Gmbh
Generation of cytotoxic tumor specific cell lines and uses thereof
An in-vitro method of activating t cells is disclosed. The method comprises incubating t cells with pathogenic cells in the presence of a multimeric peptide comprising at least two peptide monomers linked to one another, each of the at least two peptide monomers comprising at least 6 consecutive amino acids from the amino acid sequence as set forth in seq id no: 1, wherein the at least two peptide monomers are each no longer than 30 amino acids, wherein the multimeric peptide is capable of reducing binding of plif to human leukocytes under conditions which allow expansion of the t cells..
Ramot At Tel-aviv University Ltd.
Immunologically active polypeptide
Disclosed are immunomodulatory polypeptides that behave as weak tlr2 and tlr4 agonists and as potent competitive antagonists of natural pathogenic ligands for human and murine tlr2 and tlr4, that identify a subset of neutrophils in human peripheral blood leukocytes, and that elicit an unusual induced cytokine profile. Also disclosed are compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including for treating sepsis or reducing the severity or likelihood of occurrence of sepsis, in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry.
Institute Of Arthritis Research, Llc
Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules
The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh
Novel n-3 immunoresolvents: structures and actions
The invention describes novel mono-hydroxy, di-hydroxy and tri-hydroxy docosapentaenoic acid (dpa) analogues, their preparation, isolation, identification, purification and uses thereof. Resolution of inflammation is now held to be an active process where autacoids promote homeostasis.
The Brigham & Women's Hospital Inc.
Activated leukocyte conditioned supernatant and uses for wound healing
Disclosed are therapeutic, activated leukocyte conditioned supernatants, methods of making them, and methods of using the conditioned supernatants to repair or promote healing of wounds.. .
Microfluidic separation device, separation method using the same and kit for separating circulating rare cells from blood using the same
The present invention relates to a microfluidic separation device, a separation method using the same and a kit for separating circulating rare cells from blood using the same, and more particularly, to a microfluidic-based separation technology for fixing target particles of a sample, which have a specific affinity for magnetic nanoparticles, to a device by use of a magnetic material, and for isolating the sample from which the target particles have been removed. The present invention may be effectively applied to remove leukocytes from a blood sample in order to isolate circulating rare cells (crcs), particularly circulating tumor cells (otcs)..
Industry-academic Cooperation Foundation Yonsei University
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
Compounds that inhibit pi3kδ activity, including compounds that selectively inhibit pi3kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (pi3kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which pi3kδ plays a role in leukocyte function, using the compounds also are disclosed..
Nucleotide phosphate dissipation as a treatment for vascular disorders
The present invention provides a method of treating or preventing immunoinflammatory, vascular, thrombotic or ischemic disorders in a subject, the method comprises administering to the subject an agent which dissipates nucleotide phosphates or generates a product which stimulates adenosine receptors. The present invention also provides a method of treating or preventing immunoinflammatory, thrombotic or ischemic disorders in a subject by inhibiting leukocyte infiltration into a site which comprises administering to the subject an effective amount a described agent.
The Regents Of The University Of Michigan
Rapid allergy testing method
The present invention provides a method for testing an allergy capable of rapidly and highly accurately testing an allergic reaction. The method can determine whether or not a patient has an allergy or whether or not an agent that may be allergenic to a patient has an allergenicity (an allergic reactivity) in the patient.
Inhibitor of extracellular trap formation in leukocytes
The present invention has an object of providing a novel drug inhibiting formation of leukocyte extracellular traps. The present invention provides a lactoferrin-containing inhibitor of formation of leukocyte extracellular traps, and a lactoferrin-containing composition for treating a disease associated with the formation of the leukocyte extracellular traps..
Nrl Pharma, Inc.
Compositions and methods for inhibiting chemoresistance in cancer and improving response to therapy
Metastatic melanomas are highly resistant to radiation and chemotherapy from the earliest stages, which is a major factor in poor clinical outcomes. Activated leukocyte adhesion molecule (alcam)/cd166 was the gene that showed the highest correlation with detachment-induced chemoresistance.
University Of Virginia Patent Foundation
Systems and methods for automated recovery of white blood cells after producing a leuko-reduced blood product
The present disclosure relates to systems and methods for the separation of blood into blood products and, more particularly, to systems and methods that permit automated recovery of white blood cells after producing a leukocyte-reduced blood product.. .
Method and system to detect, diagnose, and monitor the progression of alzheimer's disease
Various embodiments provide methods for the detection, the diagnosis, and/or the progression monitoring of alzheimer's disease by observing the epigenetic markers in leukocytes. Methods for determining a state of alzheimer's disease are provided.
Methods for processing whole blood samples, and compositions for use in practicing the same
Methods for processing whole blood samples are provided. Aspects of the methods include depleting leukocytes from a whole blood sample to produce a leukocyte depleted sample, and then lysing red blood cells (rbcs) in the resultant leukocyte depleted sample to produce a leukocyte/rbc depleted sample.
Becton, Dickinson And Company
Methods for treating cancer
The disclosure features a method of treating cancer by lowering a patient's two gene score (tgs), particularly by increasing the number of tumor-infiltrating leukocytes. In addition, a tgs animal model and uses thereof are provided..
Microfluidic microbe detection and isolation
A method and microfluidic device useful for isolating microbes from a blood sample which includes introducing the blood sample into the sample inlet of a spiral microfluidic device; and introducing a second fluid into the sheath inlet of the microfluidic device, wherein the spiral channel terminates in a microbe outlet and a waste outlet, and wherein the spiral channel includes a length, height, and a width that define an aspect ratio adapted to isolate any microbes present in the sample along a first portion of the spiral channel terminating at the microbe outlet, and to isolate red blood cells and leukocytes along a second portion of the spiral channel terminating at the waste outlet; and collecting the microbes from the microbe outlet, thereby isolating the microbes.. .
The General Hospital Corp
Methods and systems for the reduction of leukocytes in a biological fluid
Methods and systems for removing leukocytes from a biological fluid are disclosed. The methods and systems include a chamber containing particles to which the leukocytes adhere.
Hiv viral load testing
Methods of testing hiv viral load are described. The methods comprise detecting hiv viral rna in a sample of leukocyte-depleted blood.
Diagnostics For The Real World, Ltd
Download all patent PDFs.
Bulk PDF Downloads25% Off COUPON CODE: mypdfs
Pharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen cd6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-cd6 monoclonal antibody for the diagnosis and treatment of autoimmune diseases, particularly the rheumatoid arthritis..
Centro De Inmunologia Molecular
Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
Provided are compositions and methods for prophylaxis and/or therapy of a variety of cancers which express a ny-eso-1 antigen. Included are recombinant t cell receptors (tcrs), polynucleotides encoding them, expression vectors that include the polynucleotides, and cells into which the polynucleotides have been introduced to produce modified cells, including cd4+ t cells, cd8+ t cells, natural killer t cells, γδ t cells, and progenitor cells, such as haematopoietic stem cells.
Health Research, Inc.
An implantable device that continuously regulates the blood glucose levels of a type 1 diabetes mellitus patient is provided. The device which is implanted in the bloodstream, relies on a microfluidic chip and a microsieve that efficiently separate leukocytes away from an amount of blood received and an islet compartment made up of multiple islets (beta and alpha cells) from at least one compatible donor pancreas source.
Method for identifying altered leukocyte profiles
Methods of identifying altered leukocyte profiles are disclosed. In one embodiment, counts or relative percentages of leukocyte cell types are received and constitute input data points.
Use of cd31 peptides in the treatment of thrombotic and autoimmune disorders
The present invention stems from the finding that the extracellular domain of cd31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of cd31. The invention relates to peptides corresponding to fragments of cd31 that inhibit t-cell response, and to their use in the treatment of thrombotic disorders such as atherothrombosis and autoimmune disorders..
Inserm (institute National De La Sante Et De La Recherche Medicale
Download all patent PDFs.
Bulk PDF Downloads25% Off COUPON CODE: mypdfs
Device and detection of humidity-compromised urine test strips
The timing of the reaction of moisture-sensitive reagents for detecting the presence of analytes, e.g. Leukocytes in urine samples, is used to detect when the reagents have been compromised by excess humidity.
Siemens Healthcare Diagnostics Inc.
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
Severe glomerulonephritis involves cell necrosis as well as netosis, programmed neutrophil death leading to expulsion of nuclear chromatin and neutrophil extracellular traps (nets). Histones released by neutrophils undergoing netosis killed glomerular endothelial cells, podocytes, and parietal epithelial cells.
Compositions and methods for inihibiting the activity of lar family phosphatases
A method of inhibiting and/or reducing the activity, signaling, and/or function of leukocyte-common antigen related (lar) family of phosphatases in a cell of a subject induced by proteoglycans includes administering to the cell a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of the lar family phosphatases without inhibiting binding to or activation the lar family phosphatases by the proteoglycans.. .
Case Western Reserve University
Complex targeting hepatitis b virus
A compound medicine for treating acute and chronic hepatitis b, includes a polyphenolic selenium compound having a functional group of alkali metal ion and selenium coordination complex, which has functions of directly killing hbv and destroying replication template of hbv. Auxiliary formulas thereof include high-purity oxymatrine and glycyrrhizin sulfate.
Shangha Ai Qi Ecological Technology Co., Ltd.
Activated leukocyte composition and uses for wound healing
Disclosed are therapeutic, blood-derived activated leukocyte compositions, methods of making them, and methods of using the compositions to repair or promote the prevention and healing of wounds.. .
Non-transgene transfection for therapeutic purposes
This disclosure describes compositions and methods involved in tumor suppression and inhibiting infection of cells by pathogens. Generally, the compositions include an mrna cargo that can provide a therapeutic benefit after being introduced into an epithelial cell.
Immunological function enhancing agent
A method for enhancing immune function of an animal other than human includes administering an immune function enhancing agent that contains activated lymphocytes to the animal, wherein the animal is an allogeneic animal that belongs to the same species of a donor animal, from which the activated lymphocytes are derived. The immune function enhancing agent is produced by: isolating lymphocytes from the donor animal; obtaining the activated lymphocytes by amplifying and activating the isolated lymphocytes; and producing the immune function enhancing agent using the activated lymphocytes.
Container and supporting structure for housing an organ
An apparatus intended tor evaluation, preservation and perfusion of an organ, such as a lung. The apparatus includes a container with a bottom portion, an insert portion and a lid portion.
Vivoline Medical Ab
Mac-1 antibodies and uses thereof
A method of treating a subject having or at risk of a disease or disorder associated with aberrant leukocyte-platelet interactions includes administering to the subject a therapeutically effective amount of a monoclonal antibody or antigen binding portion thereof that specifically binds to at least one of seq id no: 1, seq id no: 2, or seq id no: 3 to inhibit leukocyte arrest on adherent platelets in the subject.. .
Case Western Reserve University
Co-differentiation of monocytes from allogeneic donors
Disclosed is a method of producing non-exhausted immature dendritic cells (dcs) originating from at two different, allogeneic donors. In the method, a mixture of allogeneic leukocytes, which allogeneic leukocytes have been obtained from at least two different, allogeneic donors is provided.
Compositions and methods for treating or preventing conditions and diseases associated with mannheimia haemolytica
Particular aspects show that the signal peptide remains intact on the mature cd18 molecule on ruminant leukocytes rendering these cells susceptible to cytolysis by lkt. Comparative amino acid sequence analysis of the signal peptide of cd18 of eight ruminants and five non-ruminants revealed that the ruminant cd18 signal peptides contain ‘cleavage-inhibiting’ glutamine (q), compared to ‘cleavage-conducive’ glycine in non-ruminants, at position −5 relative to the cleavage site.
Washington State University